T. Rowe Price Associates
PDLI

T. Rowe Price Associates’s PDL BioPharma, Inc. PDLI Stock Holding History

T. Rowe Price Associates’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-28,355
Closed -$89K – 2781
2020
Q3 		$89K Buy
+28,355
New +$90.6K ﹤0.01% 2520

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

T. Rowe Price Associates's PDLI Position: Q4 2020 in Review

T. Rowe Price Associates sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 28,355 shares — an estimated $89K sold.

T. Rowe Price Associates first reported a position in PDLI in Q3 2020 and held it in 1 quarter. The position peaked at $89K in Q3 2020. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • T. Rowe Price Associates reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • T. Rowe Price Associates sold 28,355 PDL BioPharma, Inc. shares in Q4 2020, an estimated $89K.
  • T. Rowe Price Associates first reported a position in PDL BioPharma, Inc. in Q3 2020 and held it in 1 quarter.
  • T. Rowe Price Associates's PDL BioPharma, Inc. position peaked at $89K in Q3 2020.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on T. Rowe Price Associates's 13F filing for Q4 2020, filed 16 Feb 2021.